<DOC>
	<DOCNO>NCT01695226</DOCNO>
	<brief_summary>Cyclooxygenase-2 ( COX-2 ) frequently over-expressed primary breast cancer . There evidence COX-2 inhibition exert anti-tumor effect breast cancer . To determine effect COX-2 inhibition primary breast cancer , aim study change breast cancer tissue patient treat selective COX-2 inhibitor celecoxib . In single-centre double-blinded phase II study , breast cancer patient randomise receive either pre-operative celecoxib ( 400 mg ) placebo twice daily two three week . We collect fresh-frozen pre-surgical biopsy ( treatment ) surgical excision specimen ( treatment ) ass tumor change use cDNA microarray , allow study genome-wide change transcriptional level .</brief_summary>
	<brief_title>Randomized Controlled Phase II Trial Pre-operative Celecoxib Treatment Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Female patient suspect invasive breast cancer , &gt; 1 cm diameter , indication core incision biopsy Age &lt; 75 year time diagnosis Patient willing able comply study prescription Patient able give write informed consent patient registration/randomisation Pre postmenopausal patient eligible Hormone receptor positive negative patient eligible A negative pregnancy test premenopausal woman HIV , HBV HCV positivity Known hypersensitivity NSAIDs A history upper gastrointestinal bleeding Endoscopically proven upper gastrointestinal ulceration Patients use NSAIDs , include salicyclic acid Systemic use corticosteroids A history presence malignancy except adequately treat squamous cell skin cancer situ carcinoma cervix Patients treat neoadjuvant chemotherapy hormone therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>Clinical trial , Phase II</keyword>
	<keyword>Oligonucleotide Array Sequence Analysis</keyword>
</DOC>